相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
F. Lordick et al.
BRITISH JOURNAL OF CANCER (2010)
A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas
Shelly S. Lo et al.
ONCOLOGY (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
S-W Han et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Qing Sun et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
David R. Ferry et al.
CLINICAL CANCER RESEARCH (2007)
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
Michalis V. Karamouzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
Federico Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
Farin Kamangar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Targeting the epidermal growth factor receptor
BF El-Rayes et al.
BRITISH JOURNAL OF CANCER (2004)
Treatment of metastatic esophagus and gastric cancer
MA Shah et al.
SEMINARS IN ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Expression of Epidermal Growth Factor Receptor in Gastric Carcinomas
Takuo Takehana et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2003)
Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
YD Jung et al.
EUROPEAN JOURNAL OF CANCER (2002)